Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision line now displays Revision: v3.5.4, and the prior Revision: v3.5.3 entry was removed, reflecting a minor update to the page's revision history.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page’s revision identifier has been updated to v3.5.3, replacing the previous v3.5.2. This reflects a platform update without changes to the shown study details.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded Acute myeloid leukemia as a listed condition/keyword on the study page.SummaryDifference0.0%

- Check68 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check75 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.